Lentiviral Vector-Mediated Correction of a Mouse Model of Leukocyte Adhesion Deficiency Type i

Human Gene Therapy

Volumn 27, Issue 9, 2016, Pages 668-678

  Leon Rico, DIego ^a,b   Aldea, Montserrat ^a,b   Sanchez Baltasar, Raquel ^a,b   Mesa Nuñez, Cristina ^a,b   Record, Julien ^c   Burns, Siobhan O ^d,e   Santilli, Giorgia ^c   Thrasher, Adrian J ^c,f   Bueren, Juan A ^a,b   Almarza, Elena ^a,b  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^b INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD18 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LENTIVIRUS VECTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; CD34 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; BONE MARROW CELL; CELL MIGRATION; CELL STIMULATION; CONTROLLED STUDY; EX VIVO GENE TRANSFER; EXPERIMENTAL AIR POUCH INFLAMMATION; FEMALE; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE ADHESION DEFICIENCY; LEUKOCYTE ADHESION DEFICIENCY TYPE 1; LYMPHOBLASTOID CELL; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN EXPRESSION; ADMINISTRATION AND DOSAGE; ANIMAL; CELL DIFFERENTIATION; CYTOLOGY; DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETICS; LENTIVIRINAE; LEUKOCYTE-ADHESION DEFICIENCY SYNDROME; METABOLISM; NEUTROPHIL;

ANIMALS; ANTIGENS, CD18; ANTIGENS, CD34; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS; LEUKOCYTE-ADHESION DEFICIENCY SYNDROME; MICE; NEUTROPHILS;

EID: 84987858981     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2016.016     Document Type: Article

References (42)

1. Anderson DC, Springer TA. Leukocyte adhesion deficiency: An inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins. Annu Rev Med 1987;38:175-194.
2. Kishimoto TK, Hollander N, Roberts TM, et al. Heterogeneous mutations in the beta subunit common to the LFA-1, Mac-1, and p150,95 glycoproteins cause leukocyte adhesion deficiency. Cell 1987;50:193-202.
3. Simon A, Pillai S, Raghupathy P, et al. Leucocyte adhesion deficiency-1. Indian Pediatr 2002;39: 963-966.
4. Etzioni A. Genetic etiologies of leukocyte adhesion defects. Curr Opin Immunol 2009;21:481-486.
5. Harris ES, Weyrich AS, Zimmerman GA. Lessons from rare maladies: Leukocyte adhesion deficiency syndromes. Curr Opin Hematol 2013;20: 16-25.
6. Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005;94:S1-S63.
7. Bauer TR Jr., Miller AD, Hickstein DD. Improved transfer of the leukocyte integrin CD18 subunit into hematopoietic cell lines by using retroviral vectors having a gibbon ape leukemia virus envelope. Blood 1995;86:2379-2387.
8. Krauss JC, Bond LM, Todd RF 3rd, et al. Expression of retroviral transduced human CD18 in murine cells: An in vitro model of gene therapy for leukocyte adhesion deficiency. Hum Gene Ther 1991;2:221-228.
9. Wilson JM, Ping AJ, Krauss JC, et al. Correction of CD18-deficient lymphocytes by retrovirusmediated gene transfer. Science 1990;248:1413-1416.
10. Wilson RW, Yorifuji T, Lorenzo I, et al. Expression of human CD18 in murine granulocytes and improved efficiency for infection of deficient human lymphoblasts. Hum Gene Ther 1993;4:25-34.
11. Bauer TR Jr., Adler RL, Hickstein DD. Potential large animal models for gene therapy of human genetic diseases of immune and blood cell systems. ILAR J 2009;50:168-186.
12. Bauer TR Jr., Hickstein DD. Gene therapy for leukocyte adhesion deficiency. Curr Opin Mol Ther 2000;2:383-388.
13. Giger U, Boxer LA, Simpson PJ, et al. Deficiency of leukocyte surface glycoproteins Mo1, LFA-1, and Leu M5 in a dog with recurrent bacterial infections: An animal model. Blood 1987;69:1622-1630.
14. Renshaw HW, Chatburn C, Bryan GM, et al. Canine granulocytopathy syndrome: Neutrophil dysfunction in a dog with recurrent infections. J Am Vet Med Assoc 1975;166:443-447.
15. Bauer TR Jr., Allen JM, Hai M, et al. Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors. Nat Med 2008;14: 93-97.
16. Hunter MJ, Zhao H, Tuschong LM, et al. Gene therapy for canine leukocyte adhesion deficiency with lentiviral vectors using the murine stem cell virus and human phosphoglycerate kinase promoters. Hum Gene Ther 2011;22:689-696.
17. Chang AH, Stephan MT, Sadelain M. Stem cellderived erythroid cells mediate long-term systemic protein delivery. Nat Biotechnol 2006;24: 1017-1021.
18. Hunter MJ, Tuschong LM, Fowler CJ, et al. Gene therapy of canine leukocyte adhesion deficiency using lentiviral vectors with human CD11b and CD18 promoters driving canine CD18 expression. Mol Ther 2011;19:113-121.
19. Biffi A, Capotondo A, Fasano S, et al. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J Clin Invest 2006;116:3070-3082.
20. Gonzalez-Murillo A, Lozano ML, Alvarez L, et al. Development of lentiviral vectors with optimized transcriptional activity for the gene therapy of patients with Fanconi anemia. Hum Gene Ther 2010;21:623-630.
21. Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013;341: 1233158.
22. Zhang F, Thornhill SI, Howe SJ, et al. Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood 2007;110:1448-1457.
23. Gabriel R, Schmidt M, von Kalle C. Integration of retroviral vectors. Curr Opin Immunol 2012;24: 592-597.
24. Ackermann M, Lachmann N, Hartung S, et al. Promoter and lineage independent anti-silencing activity of the A2 ubiquitous chromatin opening element for optimized human pluripotent stem cell-based gene therapy. Biomaterials 2014;35: 1531-1542.
25. Pfaff N, Lachmann N, Ackermann M, et al. A ubiquitous chromatin opening element prevents transgene silencing in pluripotent stem cells and their differentiated progeny. Stem Cells 2013;31: 488-499.
26. Zhang F, Frost AR, Blundell MP, et al. A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors. Mol Ther 2010;18: 1640-1649.
27. Santilli G, Almarza E, Brendel C, et al. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther 2011;19:122-132.
28. Wilson RW, Ballantyne CM, Smith CW, et al. Gene targeting yields a CD18-mutant mouse for study of inflammation. J Immunol 1993;151:1571-1578.
29. Leon-Rico D, Aldea M, Sanchez R, et al. Brief report: Reduced expression of CD18 leads to the in vivo expansion of hematopoietic stem cells in mouse bone marrow. Stem Cells 2014;32:2794-2798.
30. Tan SM. The leucocyte beta2 (CD18) integrins: The structure, functional regulation and signalling properties. Biosci Rep 2012;32:241-269.
31. Al-Dhekri H, Al-Mousa H, Ayas M, et al. Allogeneic hematopoietic stem cell transplantation in leukocyte adhesion deficiency type 1: A single center experience. Biol Blood Marrow Transplant 2011;17:1245-1249.
32. Hamidieh AA, Pourpak Z, Hosseinzadeh M, et al. Reduced-intensity conditioning hematopoietic SCT for pediatric patients with LAD-1: Clinical efficacy and importance of chimerism. Bone Marrow Transplant 2012;47:646-650.
33. Qasim W, Cavazzana-Calvo M, Davies EG, et al. Allogeneic hematopoietic stem-cell transplantation for leukocyte adhesion deficiency. Pediatrics 2009;123:836-840.
34. Thomas C, Le Deist F, Cavazzana-Calvo M, et al. Results of allogeneic bone marrow transplantation in patients with leukocyte adhesion deficiency. Blood 1995;86:1629-1635.
35. Mukherjee S, Thrasher AJ. Gene therapy for PIDs: Progress, pitfalls and prospects. Gene 2013;525: 174-181.
36. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 2011;12:301-315.
37. Zhang L, Thrasher AJ, Gaspar HB. Current progress on gene therapy for primary immunodeficiencies. Gene Ther 2013;20:963-969.
38. Williams DA, Thrasher AJ. Concise review: Lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases. Stem Cells Transl Med 2014;3:636-642.
39. Modlich U, Navarro S, Zychlinski D, et al. Insertional transformation of hematopoietic cells by selfinactivating lentiviral and gammaretroviral vectors. Mol Ther 2009;17:1919-1928.
40. Krauss JC, Mayo-Bond LA, Rogers CE, et al. An in vivo animal model of gene therapy for leukocyte adhesion deficiency. J Clin Invest 1991;88: 1412-1417.
41. Banos R, Valeri A, Alvarez L, et al. Efficacy of a gene therapy approach using a humanized model of Fanconi anemia. Hum Gene Ther 2012;23:A111.
42. Brendel C, Kaufmann KB, Krattenmacher A, et al. Generation of X-CGD cells for vector evaluation from healthy donor CD34+ HSCs by shRNAmediated knock down of gp91phox. Mol Ther Methods Clin Dev 2014;1:14037.